Short Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 21.5%

Oculis Holding AG (NASDAQ:OCS) saw a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 490,094 shares, a decline of 21.5% from the February 26th total of 623,971 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average daily trading volume, of 521,482 shares, the days-to-cover ratio is presently 0.9 days.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on OCS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Thursday, January 22nd. Needham & Company LLC raised their price target on Oculis from $36.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Stifel Nicolaus upped their target price on shares of Oculis from $40.00 to $50.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Lifesci Capital initiated coverage on shares of Oculis in a report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price target for the company. Finally, Wall Street Zen cut shares of Oculis from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.86.

Oculis Stock Performance

Shares of OCS stock opened at $24.69 on Friday. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.96 and a quick ratio of 5.96. The business has a fifty day moving average of $27.43 and a 200 day moving average of $22.51. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -10.88 and a beta of 0.29. Oculis has a 1 year low of $14.00 and a 1 year high of $30.68.

Oculis (NASDAQ:OCS) last issued its earnings results on Tuesday, March 3rd. The company reported ($0.51) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 62.12%. The firm had revenue of $0.50 million during the quarter, compared to analysts’ expectations of $0.14 million. As a group, research analysts expect that Oculis will post -2.09 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of OCS. Gildi lifeyrissjodur purchased a new stake in Oculis in the 4th quarter worth approximately $50,250,000. Aberdeen Group plc increased its holdings in shares of Oculis by 39.4% during the 4th quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after purchasing an additional 493,827 shares in the last quarter. SR One Capital Management LP lifted its stake in shares of Oculis by 98.8% in the 4th quarter. SR One Capital Management LP now owns 641,022 shares of the company’s stock valued at $12,801,000 after purchasing an additional 318,522 shares during the period. Perceptive Advisors LLC purchased a new stake in Oculis during the fourth quarter worth $9,862,000. Finally, Alyeska Investment Group L.P. grew its position in Oculis by 152.3% during the fourth quarter. Alyeska Investment Group L.P. now owns 331,332 shares of the company’s stock valued at $6,617,000 after buying an additional 200,000 shares during the period. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.